Neurochase specializes in the targeted delivery of therapeutics to the central nervous system through precision-engineered delivery systems that enhance drug bioavailability. This technology ensures that medications effectively reach their intended sites of action, improving treatment outcomes for neurological disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many neurological diseases lack effective treatments because therapeutic agents cannot be delivered precisely and safely to the central nervous system (CNS). Traditional methods often fail due to the blood-brain barrier and the challenges of achieving targeted drug distribution within the brain. This limitation hinders the success of promising gene therapies and other advanced treatments.
Solution
Neurochase is developing a next-generation CNS drug delivery platform based on convection-enhanced delivery (CED) to improve the treatment of neurological diseases. Their technology aims to overcome the limitations of systemic drug administration by directly infusing therapeutic agents into targeted brain regions. By bypassing the blood-brain barrier and ensuring precise drug distribution, Neurochase's delivery system enhances the bioavailability and efficacy of gene therapies and other advanced treatments. The company also offers consultancy and training services to support pre-clinical and clinical trials utilizing direct CNS delivery methods.
Target Audience
Neurochase's primary customers include pharmaceutical and biotechnology companies developing gene therapies and other advanced treatments for neurological disorders, as well as CROs and research institutions conducting pre-clinical and clinical trials.
Features
- Proprietary Convection Enhanced Delivery (CED) devices for targeted drug infusion into the CNS
- Support for protocol development and optimization for pre-clinical studies
- Surgical workflow optimization and surgeon training for clinical trials
- Expertise in direct delivery of gene therapies and other therapeutics to the CNS
- Consultancy services for biotech and pharmaceutical companies
- Support for stereotactic equipment, devices, and training for CROs
- Access to GLP facilities and preclinical devices translatable to humans